• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InvestorNewsBreaks – ProPhase Labs Inc. (NASDAQ: PRPH) Closes $23.6M Sale to Focus on Core Businesses

By: Investor Brand Network
April 16, 2025 at 12:25 PM EDT

ProPhase (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, earlier this year announced the closing of the sale of its wholly owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings Inc. (collectively “Pharmaloz” or “PMI”), to a private equity group based in Houston, Texas. The transaction’s aggregate deal was valued at approximately $23.6 million, which immediately bolstered ProPhase’s balance sheet and liquidity by eliminating over $20 million in debt, payables, and other contingent liabilities. Overall, the transaction better positioned ProPhase to focus on its promising and high-value core businesses.

To view the full press release, visit https://ibn.fm/KKdCD

About ProPhase Labs Inc.

ProPhase is a next-generation biotech, genomics and diagnostics company. Its goal is to create a healthier world with bold action and the power of insight. ProPhase is revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. ProPhase develops, manufactures, and commercializes health and wellness solutions to enable people to live their best lives. The company is committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore its potential for long-term value.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

More News

View More
FICO’s Big Dip Could Be the Best Buying Chance of the Year
October 13, 2025
Via MarketBeat
Tickers EFX FICO
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
October 13, 2025
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
October 13, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
October 13, 2025
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
October 13, 2025
Via MarketBeat
Tickers DAL
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+0.00 (0.00%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap